- Home
- CODA vs HOWL Comparison
CODA vs HOWL Comparison
Compare CODA & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODA
- HOWL
- Stock Information
- Founded
- CODA 1994
- HOWL 2017
- Country
- CODA United States
- HOWL United States
- Employees
- CODA N/A
- HOWL N/A
- Industry
- CODA Industrial Machinery/Components
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- CODA Industrials
- HOWL Health Care
- Exchange
- CODA Nasdaq
- HOWL Nasdaq
- Market Cap
- CODA 88.8M
- HOWL 64.5M
- IPO Year
- CODA N/A
- HOWL 2021
- Fundamental
- Price
- CODA $8.26
- HOWL $1.44
- Analyst Decision
- CODA Strong Buy
- HOWL Strong Buy
- Analyst Count
- CODA 1
- HOWL 5
- Target Price
- CODA $11.00
- HOWL $7.20
- AVG Volume (30 Days)
- CODA 80.8K
- HOWL 148.8K
- Earning Date
- CODA 09-15-2025
- HOWL 11-06-2025
- Dividend Yield
- CODA N/A
- HOWL N/A
- EPS Growth
- CODA 15.09
- HOWL N/A
- EPS
- CODA 0.30
- HOWL N/A
- Revenue
- CODA $24,347,217.00
- HOWL N/A
- Revenue This Year
- CODA $30.82
- HOWL N/A
- Revenue Next Year
- CODA $20.84
- HOWL N/A
- P/E Ratio
- CODA $26.33
- HOWL N/A
- Revenue Growth
- CODA 29.34
- HOWL N/A
- 52 Week Low
- CODA $5.76
- HOWL $0.60
- 52 Week High
- CODA $9.89
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- CODA 55.46
- HOWL 61.16
- Support Level
- CODA $7.85
- HOWL $1.38
- Resistance Level
- CODA $8.80
- HOWL $1.49
- Average True Range (ATR)
- CODA 0.40
- HOWL 0.07
- MACD
- CODA 0.02
- HOWL 0.01
- Stochastic Oscillator
- CODA 54.62
- HOWL 72.50
About CODA Coda Octopus Group Inc. Common stock
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.